Results 81 to 90 of about 5,796 (217)

Effects of Palivizumab Guideline Changes on RSV Admissions in Patients with Congenital Heart Disease and Prematurity

, 2021
John Pham, Stephen Nageotte, Jon Detterich, Grace C. Kung   +3 more
openalex   +2 more sources

Palivizumab em contexto domiciliário

, 2012
O Departamento de Pediatria, nomeadamente a UCIENP, através do Projeto de Apoio Domiciliário ao Recém-Nascido internado na UCIEN, formou em 2009, uma equipa multidisciplinar de apoio domiciliário, em parceria com a Fundação do Gil, procurando contribuir para a melhoria na qualidade de vida da criança e sua família.
Cunha, A, Amaral, J, Costa, M, Lopez, M
openaire   +2 more sources

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria
Objective: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source

P81 What is the ideal target preterm population that might benefit from the expensive palivizumab prophylaxis? [PDF]

, 2017
L Tsilika, Dushyant Batra, AP Prayle, MN Hurley, Jayesh Bhatt   +4 more
openalex   +1 more source

MODERN POTENTIALITIES OF IMMUNOPROPHYLAXIS OF SEVERE COURSE OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH THE CONSEQUENCES OF PERINATAL PATHOLOGY

Педиатрическая фармакология, 2011
To a risk group of a heavy course of the respiratory syncytial viral (RSV) infection could be ascribed preterm infants, born before the 35th week of gestation inclusive, as well as children under 2 years old with the bronchopulmonary dysplasia or ...
L.S. Namazova-Baranova, I.V. Davydova, T.V. Turti, I.A. Belyaeva, V.V. Altunin   +4 more
doaj   +2 more sources

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel
Tianzhou Yu, William V. Padula, Leah Yieh, Cynthia L. Gong   +3 more
doaj   +1 more source

Impact of an Antimicrobial Stewardship Policy to Restrict Palivizumab Use [PDF]

, 2017
Torsten Joerger, Shannon Chan, Sanjeev Swami, Lori Handy   +3 more
openalex   +1 more source

Costo-efectividad incremental del palivizumab en prematuros en la Seguridad Social de Costa Rica. 2010-2017 [PDF]

, 2020
Luis Guillermo Jiménez Herrera, Manuel Collado Herrera, Ana María Gálvez Gónzález   +2 more
openalex   +1 more source

73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)

, 2019
Ian Mitchell, Mahwesh Saleem, Abby Li, Krista L. Lanctôt, Bosco Paes   +4 more
openalex   +2 more sources

Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates [PDF]

, 2017
Ludwig Gortner
openalex   +1 more source